Pharmbio Korea Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1999-05-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.pharmbio.co.kr
Clinical Trials
9
Active:0
Completed:3
Trial Phases
4 Phases
Phase 1:2
Phase 3:4
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (50.0%)Phase 1
2 (25.0%)Not Applicable
1 (12.5%)Phase 4
1 (12.5%)A Study to Evaluate Safety and Efficacy of PBK_M2502
Not Applicable
Not yet recruiting
- Conditions
- Intestinal DiseaseColonic DiseasesGastrointestinal DiseaseDigestive System Disease
- Interventions
- Drug: PBK_M2502 1-DayDrug: PBK_M2502 2-Day
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT07114406
- Locations
- 🇰🇷
Kyung Hee University Hospital at Gangdong, Seoul, Gangdong-gu, Korea, Republic of
Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Drug-Drug Interaction Healthy Volunteers
- Interventions
- Drug: R1_PBK_M2301(Levocloperastine 60mg)Drug: R2_PBK_M2301 (Pelargonium sidoides extract)
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT07017335
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06154187
- Locations
- 🇰🇷
The Catholic University of Korea Yeouido Saint Mary's Hospital, Seoul, Korea, Republic of
A Study to Evaluate Safety and Efficacy of PBK_M2101
Phase 3
Recruiting
- Conditions
- Intestinal DiseaseDigestive System DiseaseColonic DiseasesGastrointestinal Disease
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 246
- Registration Number
- NCT05923918
- Locations
- 🇰🇷
Seoul Asan Medical Center, Seoul, Korea, Republic of
Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea
Phase 3
- Conditions
- Acute Pain
- Interventions
- Drug: PBK_L1704 0.5mgDrug: PBK_L1704 0.35mgDrug: Placebo
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Pharmbio Korea Co., Ltd.
- Target Recruit Count
- 225
- Registration Number
- NCT05509868
- Locations
- 🇰🇷
Seoul Asan medical Center, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found